Difference between revisions of "Hypericum-agomelatine"

From Psychiatrienet
Jump to: navigation, search
Line 6: Line 6:
 
| start =  
 
| start =  
 
* Start administration of agomelatine the next day in a dosage of 25 mg/day.
 
* Start administration of agomelatine the next day in a dosage of 25 mg/day.
* If necessary, increase dosage of agomelatine to 50 mg/day. }}
+
* If necessary, increase dosage of agomelatine to 50 mg/day.  
 +
{{review}}
 +
}}

Revision as of 12:49, 7 October 2015

Hypericum
Type Antidepressant
Group other
links
EMEA 10130408en
PubMed Hypericum
Kompas (Dutch) hypericum extract
Wikipedia St John's wort
Agomelatine
Type Antidepressant
Group other
links
ATC-code N06AX22
EMEA valdoxan
PubChem 82148
PubMed Agomelatine
Kompas (Dutch) Agomelatine
Wikipedia Agomelatine

Switch medication from hypericum to agomelatine.[1] [2]

Nietinrijdenbord.png Stop hypericum
  • The administration of hypericum can be stopped abruptly.
Eenrichtingbord.png Start agomelatine
  • Start administration of agomelatine the next day in a dosage of 25 mg/day.
  • If necessary, increase dosage of agomelatine to 50 mg/day.
  • This switch is currently being reviewed.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.